By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


SEARCH JOBS



Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website – www.regeneron.com
Check out our openings – http://careers.regeneron.com


Key Statistics


Email:
Ownership: Public

Web Site: Regeneron
Employees: 2300+
Symbol: REGN
 





Collaborations

Sanofi US 

Bayer 

Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotech 





Company News
No Early Success for Regeneron (REGN) and Sanofi (SNY)'s Cholesterol Drug Praluent 11/17/2016 5:52:03 AM
Regeneron (REGN) And Sanofi (SNY) Present Results From Phase 3 MONARCH Study Of Investigational Sarilumab At American College of Rheumatology Annual Meeting 11/16/2016 7:50:55 AM
Regeneron (REGN) And Sanofi (SNY) To Present Data From Phase 3 Praluent (Alirocumab) Injection Clinical Trials At AHA Scientific Sessions 2016 11/11/2016 11:14:17 AM
Regeneron (REGN) Reports Third Quarter 2016 Financial And Operating Results 11/4/2016 9:09:38 AM
OUCH! FDA Spurns Regeneron (REGN), Sanofi (SNY)'s RA Drug Over Plant Deficiencies 10/31/2016 6:03:46 AM
Regeneron (REGN) And Teva (TEVA) Provide Update On Fasinumab Clinical Development Programs 10/17/2016 1:35:33 PM
FDA Slaps Hold on Regeneron (REGN), Teva (TEVA)'s Pain Drug Fasinumab 10/17/2016 5:27:35 AM
Regeneron (REGN) Bets $315 Million on Ocular Therapeutix (OCUL) for an Upgraded Form of Eylea 10/13/2016 5:30:27 AM
Regeneron (REGN) Could Have Another Blockbuster in This Drug 10/10/2016 6:47:29 AM
Regeneron (REGN) To Report Third Quarter 2016 Financial And Operating Results And Host Conference Call And Webcast On November 4, 2016 10/7/2016 8:46:03 AM
12345678910...
//-->